TP53 and neoplasm: CDK5 siRNA-DOPC plus paclitaxel produced greater inhibition of tumor growth than any other group for each of the two models (Fig 6A) and silencing CDK5 decreased p-AKT, increased TP53 and p27Kip1in vivo (S5 Fig).